Literature DB >> 202659

Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects.

M Berman, M Hall, R I Levy, S Eisenberg, D W Bilheimer, R D Phair, R H Goebel.   

Abstract

The kinetics of apolipoproteins B and C were studied in 14 normal and hyperlipoproteinemic subjects after injection of exogenously (125)I-labeled very low density lipoprotein (VLDL) particles. Plasma radioactivities of apoB and apoC were determined over a period of 4 days in VLDL (d < 1.006) and total radioactivity in intermediate (IDL) (1.006 < d < 1.019), low (LDL) (1.019 < d < 1.063), and high (HDL) (1.063 < d < 1.21) density lipoproteins. The data were analyzed by the use of a model, developed mostly from these data, with the following results. The VLDL particle undergoes a series of incremental density changes, most likely due to a number of delipidation steps, during which apoB stays with the particle until the density reaches the IDL range. There is, however, a loss of apoC associated with these delipidation steps. In our normal subjects, all IDL apoB eventually becomes LDL. In our hyperlipemic subjects some of the apoB on IDL is also degraded directly. The apoC lost by VLDL and IDL recycles to HDL, and most of it is picked up again by newly synthesized VLDL. There is a slowdown of the stepwise delipidation process in all hyperlipemic individuals studied. Three additional features became apparent in the type III subjects. First, there is a significant increase (a factor of 2 compared to normal) in the apoB synthesis rate by way of VLDL; second, there is an induced direct apoB synthesis pathway by way of IDL (and/or LDL); third, a bypass of the regular stepwise VLDL delipidation pathway is induced by which VLDL particles lose apoC but none of their apoB, thereby forming a new particle with metabolic properties similar to LDL, but with a density still in the VLDL density range. Two type III patients treated with nicotinic acid and clofibrate showed a sharp decrease in their VLDL apoB synthesis rates. This was somewhat compensated by an increased IDL apoB synthesis rate. A type I patient on a medium chain triglyceride diet also showed a number of metabolic changes, including reduced VLDL apoB synthesis and the induction of considerable IDL and/or LDL apoB synthesis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 202659

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  41 in total

1.  The composition and metabolism of high density lipoprotein subfractions.

Authors:  E J Schaefer; D M Foster; L L Jenkins; F T Lindgren; M Berman; R I Levy; H B Brewer
Journal:  Lipids       Date:  1979-05       Impact factor: 1.880

2.  The role of high density lipoprotein apolipoprotein CII in triglyceride metabolism.

Authors:  M L Kashyap; L S Srivastava; B A Hynd; G Perisutti; D W Brady; P Gartside; C J Glueck
Journal:  Lipids       Date:  1978-12       Impact factor: 1.880

3.  Kinetic modeling and the rise of systems pharmacology.

Authors:  Robert D Phair
Journal:  J Lipid Res       Date:  2015-11-20       Impact factor: 5.922

4.  Measurement of very low density and low density lipoprotein apolipoprotein (Apo) B-100 and high density lipoprotein Apo A-I production in human subjects using deuterated leucine. Effect of fasting and feeding.

Authors:  J S Cohn; D A Wagner; S D Cohn; J S Millar; E J Schaefer
Journal:  J Clin Invest       Date:  1990-03       Impact factor: 14.808

5.  Unaltered catabolism of desialylated low-density lipoprotein in the pig and in cultured rat hepatocytes.

Authors:  A D Attie; D B Weinstein; H H Freeze; R C Pittman; D Steinberg
Journal:  Biochem J       Date:  1979-06-15       Impact factor: 3.857

6.  Central role of high density lipoprotein in plasma free cholesterol metabolism.

Authors:  C C Schwartz; Z R Vlahcevic; M Berman; J G Meadows; R M Nisman; L Swell
Journal:  J Clin Invest       Date:  1982-07       Impact factor: 14.808

7.  Splanchnic metabolism of plasma apolipoprotein B: studies of artery-hepatic vein differences of mass and radiolabel in fasted human subjects.

Authors:  P R Turner; N E Miller; C Cortese; W Hazzard; J Coltart; B Lewis
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

8.  Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.

Authors:  S Eisenberg; D Gavish; Y Oschry; M Fainaru; R J Deckelbaum
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

9.  Improved cholesterol phenotype analysis by a model relating lipoprotein life cycle processes to particle size.

Authors:  Daniël B van Schalkwijk; Albert A de Graaf; Ben van Ommen; Kees van Bochove; Patrick C N Rensen; Louis M Havekes; Niek C A van de Pas; Huub C J Hoefsloot; Jan van der Greef; Andreas P Freidig
Journal:  J Lipid Res       Date:  2009-06-10       Impact factor: 5.922

10.  Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

Authors:  T Demant; D Bedford; C J Packard; J Shepherd
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.